XZB-0004 is a novel and potent small molecule inhibitor of receptor tyrosine kinase AXL currently being tested in a phase I trial in R/R patients with AML and MDS (NCT05740917). The gene discussed is NTRK1; the disease is acute myeloid leukemia.